Replying to @celanesecorp
Asymmetric phase-transfer catalysis is elegant and scalable. Catalyst cost is manageable.
@pharmaron
Replying to @celanesecorp
Asymmetric phase-transfer catalysis is elegant and scalable. Catalyst cost is manageable.
Replying to @airliquide
We use recombinant albumin fusion to extend the circulating half-life.
Replying to @sinopharm_cnsc
The key challenge is balancing yield optimization with impurity profile control at production scale.